Literature DB >> 27960088

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.

Jin-Sung Park1, Il-Kug Kim2, Sangyeul Han3, Intae Park1, Chan Kim2, Jeomil Bae4, Seung Ja Oh5, Seungjoo Lee6, Jeong Hoon Kim6, Dong-Cheol Woo7, Yulong He8, Hellmut G Augustin9, Injune Kim2, Doheon Lee10, Gou Young Koh11.   

Abstract

A destabilized tumor vasculature leads to limited drug delivery, hypoxia, detrimental tumor microenvironment, and even metastasis. We performed a side-by-side comparison of ABTAA (Ang2-Binding and Tie2-Activating Antibody) and ABA (Ang2-Blocking Antibody) in mice with orthotopically implanted glioma, with subcutaneously implanted Lewis lung carcinoma, and with spontaneous mammary cancer. We found that Tie2 activation induced tumor vascular normalization, leading to enhanced blood perfusion and chemotherapeutic drug delivery, markedly lessened lactate acidosis, and reduced tumor growth and metastasis. Moreover, ABTAA favorably altered the immune cell profile within tumors. Together, our findings establish that simultaneous Tie2 activation and Ang2 inhibition form a powerful therapeutic strategy to elicit a favorable tumor microenvironment and enhanced delivery of a chemotherapeutic agent into tumors.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  M2-like TAM; Tie2 activation; angiopoietin-2; enhanced drug delivery; tumor microenvironment; tumor vasculature; tumor vessel normalization

Mesh:

Substances:

Year:  2016        PMID: 27960088     DOI: 10.1016/j.ccell.2016.10.018

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  98 in total

Review 1.  New Directions in Anti-Angiogenic Therapy for Glioblastoma.

Authors:  Nancy Wang; Rakesh K Jain; Tracy T Batchelor
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

2.  Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma.

Authors:  Laurie Sorenson; Yanfen Fu; Tressa Hood; Sarah Warren; Troy A McEachron
Journal:  Oncoimmunology       Date:  2019-06-27       Impact factor: 8.110

Review 3.  Microenvironmental regulation of tumour angiogenesis.

Authors:  Michele De Palma; Daniela Biziato; Tatiana V Petrova
Journal:  Nat Rev Cancer       Date:  2017-07-14       Impact factor: 60.716

4.  Cancer: Tumour vessel normalization takes centre stage.

Authors:  Megan Cully
Journal:  Nat Rev Drug Discov       Date:  2017-02-02       Impact factor: 84.694

5.  A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling.

Authors:  Adam C Mirando; Jikui Shen; Raquel Lima E Silva; Zenny Chu; Nicholas C Sass; Valeria E Lorenc; Jordan J Green; Peter A Campochiaro; Aleksander S Popel; Niranjan B Pandey
Journal:  JCI Insight       Date:  2019-02-21

6.  Normalizing Tumoral Vessels to Treat Cancer: An Out-of-the-Box Strategy Involving TIE2 Pathway.

Authors:  Juan Fueyo; Mohammad B Hossain; Teresa Nguyen; Candelaria Gomez-Manzano
Journal:  Transl Cancer Res       Date:  2017-03       Impact factor: 1.241

Review 7.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.

Authors:  Kabir A Khan; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

Review 8.  The Reciprocity between Radiotherapy and Cancer Immunotherapy.

Authors:  Yifan Wang; Zhi-Gang Liu; Hengfeng Yuan; Weiye Deng; Jing Li; Yuhui Huang; Betty Y S Kim; Michael D Story; Wen Jiang
Journal:  Clin Cancer Res       Date:  2018-11-09       Impact factor: 12.531

9.  STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.

Authors:  Hannah Yang; Won Suk Lee; So Jung Kong; Chang Gon Kim; Joo Hoon Kim; Sei Kyung Chang; Sewha Kim; Gwangil Kim; Hong Jae Chon; Chan Kim
Journal:  J Clin Invest       Date:  2019-07-25       Impact factor: 14.808

Review 10.  Therapeutic targeting of the angiopoietin-TIE pathway.

Authors:  Pipsa Saharinen; Lauri Eklund; Kari Alitalo
Journal:  Nat Rev Drug Discov       Date:  2017-05-19       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.